-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 20, 2022, the HKUST Council unanimously approved the appointment of Professor Ye Yuru as the next president of HKUST, effective from October 19, 202 Professor Ye Yuru will be the first female president of HKUST since its establishment in 199 It is also the first female president of eight universities in Hong Kong after the predecessor of the University of Education, Hong Kong Institute of Education Xu Mei-.
Professor Ye Yuru joined HKUST in 1993 and was appointed as the Vice President (Research and Development) in 2016 until April this year; he has been the Honorary President of the Association since 201
Professor Ye Yuru's remarkable achievements and contributions are widely recognized international.
Professor Ye is currently an academician of the Chinese Academy of Sciences, a foreign academician of the National Academy of Sciences, a foreign honorary academician of the American Academy of Arts and Sciences, an academician of the World Academy of Sciences, a founding academician of the Hong Kong Academy of Sciences, and the chairman of the Council of the Guangdong-Hong Kong-Macao Greater Bay Area Academician Allian.
---- HKBMIA Hong Kong Biomedical Innovation Association----
HKBMIA is committed to building an innovative and international biomedical technology industry platform for Hong Ko.
Actively introduce outstanding overseas biomedical innovation and technology projects and industries, and provide assistance in various aspects, including formulating industrialization and business development plans, financing and listing, corporate governance and auditing, R&D technology, patent protection, valuation, policies and regulations , clinical trial design and planning to enter the domestic mark.